Categories Health Care, IPO, Others
IPO News: Here’s what to know when Sera Prognostics goes public this week
Sera will offer 4.7 million shares at a price range of $15-17 per share
The healthcare industry continues to grow at a rapid pace with diagnostic services playing an important role in this space. Women’s health diagnostic company Sera Prognostics is set to go public this week and here are a few points to note about the transaction:
IPO details
Sera Prognostics is scheduled to go public on Thursday, July 15. The company is expected to begin trading on NASDAQ under the ticker symbol SERA. Sera will offer 4.7 million shares at a price range of $15-17 per share to raise $75 million. The IPO will be managed by Citigroup, Cowen and William Blair.
Company intro
Sera Prognostics develops diagnostic tests that help predict risks associated with pregnancy such as premature delivery. The company uses its proteomics and bioinformatics platform to discover protein biomarkers in blood that can predict dynamic changes during pregnancy. This data helps in predicting various pregnancy-related complications such as the risk of a preterm birth. This will help in significantly improving maternal and neonatal health.
Sera’s product, the PreTRM test, is the only commercially available blood-based biomarker test that helps in accurately predicting the risk of a premature delivery. It is a non-invasive blood test given to pregnant women during weeks 19 or 20 of gestation that predicts the risk of the mother delivering spontaneously before 37 weeks.
Sera has a collaboration with health insurer Anthem Inc. (NYSE: ANTM) under which Anthem will make the PreTRM test available to eligible pregnant members as part of a multi-year contract. Anthem has more than 43 million members and its health plans cover over 10% of pregnancies in the US annually. Sera believes this alliance will de-risk initial commercialization and pave the way for broader market adoption for its PreTRM test.
Financials
Sera generated revenues of $25,000 in FY2020. The company delivered a net loss of $19.8 million during the same period. The company was founded in 2008 and has 76 employees.
Market opportunity
There are approx. 140 million births worldwide each year of which around 25% are affected by various complications such as preterm birth, preeclampsia, fetal growth restriction, stillbirth and gestational diabetes among others. In the US alone, there are around 3.8 million births annually and over 10% of these pregnancies result in preterm birth with profound health consequences to the mother and baby.
These health consequences are estimated to lead to costs of approx. $25 billion annually in the US. Sera believes its biomarker tests can help mitigate the complications associated with premature birth as well as reduce healthcare costs.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%
Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss
Key metrics from Nike’s (NKE) Q2 2025 earnings results
NIKE, Inc. (NYSE: NKE) reported total revenues of $12.4 billion for the second quarter of 2025, down 8% on a reported basis and down 9% on a currency-neutral basis. Net
FDX Earnings: FedEx Q2 2025 adjusted profit increases; revenue dips
Cargo giant FedEx Corporation (NYSE: FDX), which completed an organizational restructuring recently, announced financial results for the second quarter of 2025. Second-quarter earnings, excluding one-off items, were $4.05 per share,